HAII

Digital Therapeuticshaii.co.kr

Company typePrivate
Founded2016
HeadquartersSeoul, South Korea
Headcount51–100
GTM typeB2B
OfferingSoftware

HAII firmographics

Firmographics

Name: HAII
Legal name: HAII Corp.
Website: https://haii.co.kr
Company type: Private
Founded year: 2016
Operating status: Operating
Headcount range: 51–100 employees
Ownership category
akta.pro rank

HAII industry classification

Industry

Product category: Digital Therapeutics
NAICS: Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)
SIC: Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry: SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
akta.pro secondary industries: Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

Digital therapeutics
Digital biomarkers
AI healthcare
Speech therapy software
Mental health platform

Where HAII is headquartered

Location

Headquarters

HQ city: Seoul
HQ country: South Korea
HQ region: Asia

Offices1 record

Markets served

HAII business model

Business model

GTM type: B2B
Offering type: Software
Cost components: Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

Digital Therapeutics Products: Revenue from digital therapeutic products such as Anzeilax for generalized anxiety disorder, Repeech for speech therapy, Rehave, Forme, and Alzguard targeting various neurological and psychological conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

HAII product offering

Product offering

Core offering

HAII develops and delivers prescription digital therapeutics and a digital biomarker platform that uses AI to analyze smartphone-sensor data (microphone, camera, touchscreen) for diagnosis, treatment, and monitoring of mental health and neurological conditions. Its portfolio targets generalized anxiety disorder (Anzeilax), post-stroke dysarthria (Repeech), rehabilitation (Rehave), cognitive/physical therapy (Forme), cognitive assessment (Mindcheck), and dementia care (Alzguard), sold primarily to hospitals and medical institutions in South Korea.

Product overview

HAII operates as a digital therapeutics company offering a platform of Health AI services built on AI technology and digital biomarkers. The portfolio includes five named digital therapeutic products: Anzeilax (for generalized anxiety disorder), Repeech (digital speech therapy for post-stroke dysarthria), Rehave (rehabilitation therapy), Forme (cognitive/physical rehabilitation), Mindcheck (cognitive assessment), and Alzguard (dementia care). These products share a common technological foundation — HAII's digital biomarker platform (ACE: Action, Cognition, Emotion) — which uses smartphone sensors (microphone, camera, touchscreen) to collect and analyze physiological, behavioral, and psychological indicators via AI for diagnosis, treatment, and monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

Anzeilax Digital theranostics product for generalized anxiety disorder (GAD), developed as a digital therapeutic with clinical trials approved by the Ministry of Food and Drug Safety (MFDS). Built on HAII's AI-driven digital biomarker platform and intended for prescription use in clinical settings.
Repeech Digital speech therapy solution developed in collaboration with Seoul Ewha Seoul Hospital, targeting post-stroke dysarthria patients. Offered as a smartphone-based therapy application backed by peer-reviewed clinical research.
Rehave Digital therapeutic product developed in collaboration with Chungnam National University Hospital, focused on rehabilitation and functional recovery.
Forme Digital therapeutic product developed in collaboration with Kyungpook National University Hospital and Forme, targeting cognitive or physical rehabilitation.
Mindcheck Digital therapeutic or cognitive assessment product developed in collaboration with Forme, focused on mental health monitoring and cognitive evaluation.
Alzguard Digital therapeutic product developed in collaboration with Kim Ye-shin (Alzguard), focused on Alzheimer's or dementia care.

Quantifiable outcome

Industry-leading accuracy rates for AI-based diagnostic products
+2 more outcomes

Companies that use HAII

Customer profile

Named customers14 records

Segments2 records

Ideal customer profiles2 records

HAII technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

HAII partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Maeil Dairy and Maeil Health NutritioncoreStrategic or Co-development Partner · 26 January 2026Three-way MOU signed to build a future healthcare model combining nutrition solutions and digital healthcare technology. HAII's AI and data analysis technologies will be incorporated into Maeil Dairy's and Maeil Health Nutrition's scientific nutritional design capabilities, with plans to expand into Digital Therapeutics. The partnership includes joint development of data-based healthcare programs and mid- to long-term research and commercialization.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

HAII competitors and assessment

Company assessment

Direct peers

Akili Interactive: US-listed digital therapeutics company (now went private via acquisition) that develops FDA-cleared prescription DTx (EndeavorRx, EndeavorRx for ADHD). Directly comparable to HAII as a prescription-grade DTx developer leveraging AI and digital biomarkers, albeit with US FDA pathway rather than Korean MFDS.
Click Therapeutics: US DTx company developing prescription digital therapeutics for conditions including depression, migraine, and smoking cessation. Comparable to HAII's Anzeilax/Mindcheck as a clinically validated DTx pipeline targeting mental and neurological indications.
Kaia Health: Digital therapeutics company with smartphone-delivered programs for musculoskeletal pain and COPD rehabilitation. Comparable to HAII's Rehave and Forme rehabilitation products as a DTx player in musculoskeletal and rehab indications.
Better Therapeutics: US prescription digital therapeutics company developing FDA-authorized DTx for cardiometabolic and behavioral conditions. Comparable to HAII as a clinically validated DTx pipeline player pursuing SaMD-style regulatory clearance.
Woebot Health: AI-driven mental health DTx/chatbot company delivering cognitive behavioral therapy via smartphone. Comparable to HAII's mental health portfolio (Anzeilax, Mindcheck) and its AI-based smartphone biomarker approach.
Big Health: Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), both of which intersect directly with HAII's Anzeilax for generalized anxiety disorder. Both companies use behavioral and AI-driven interventions delivered via smartphone.

Broad incumbents

Headspace Health: Established mental health platform combining Headspace and Ginger for therapy, coaching, and self-guided mental health programs. Comparable to HAII's mental health portfolio as a larger incumbent in digital behavioral health, though wider in scope (B2B benefits) than HAII's regulated DTx.

Regional players

Kakao Healthcare: South Korea-based digital healthcare subsidiary of Kakao group building AI-driven health management and DTx platforms. Comparable as a domestic Korean competitor leveraging smartphone UX and digital biomarkers for health monitoring.
VUNO: South Korean AI medical software company developing AI-based diagnostic and decision-support solutions approved by MFDS, including imaging and clinical AI. Comparable as a Korean AI-health player pursuing regulatory-grade clinical AI products, sharing go-to-market via Korean hospital channels.

Emerging players

Limbic: UK-based DTx/AI platform supporting mental health treatment selection and patient engagement, including for anxiety and depression. Comparable emerging player to HAII in AI-enabled behavioral health interventions, though focused upstream of HAII's clinical SaMD model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

HAII financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HAII leadership team

Management profile

Number of profiles

Profiles1 record

HAII funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HAII M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAII

What does HAII do?

Is HAII a public or private company?

HAII is a private company. It is classified as venture growth investor backed and is currently operating.

When was HAII founded?

HAII was founded in 2016. It employs 51 to 100 people.

Where is HAII based?

HAII is headquartered in Seoul, South Korea, in the Asia region.

How does HAII make money?

One revenue line is on record: digital Therapeutics Products.

Who are HAII's main competitors?

Direct peers on record are Akili Interactive, Click Therapeutics, Kaia Health, Better Therapeutics, Woebot Health and Big Health. Headspace Health is listed as a broad incumbent. Regional players are Kakao Healthcare and VUNO. Limbic is listed as an emerging player.

Does HAII have an API?

No public API is recorded for HAII.

What industry is HAII in?

HAII's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 621420 and its SIC code is 8000.